Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction?

Lancet

Volumn 347, Issue 8994, 1996, Pages 102-103

  Massy, Ziad A ^a   Keane, William F ^a   Kasiske, Bertram L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLYCOPROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVALONIC ACID; SIMVASTATIN;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TISSUE LEVEL; HUMAN; LIPID METABOLISM; MEMBRANE FLUIDITY; NONHUMAN; PRENYLATION; PRIORITY JOURNAL;

EID: 0030058148     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90217-2     Document Type: Article

References (18)

1. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994; 343: 1554-55.
2. Gotto AM. Lipid lowering, regression, and coronary events. A review of the interdisciplinary council on lipids and cardiovascular risk intervention, seventh council meeting. Circulation 1995; 92: 646-56.
3. Levine GN, Keany JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995; 332: 512-21.
4. Goldstein JL, Brown MS. Regulation of mevalonate pathway. Nature 1990; 343: 425-30.
5. Corsini A, Raiteri M, Soma M, Fumagalli R, Paoletti R. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res 1991; 23: 173-80.
6. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993; 93: 83-87.
7. Sumi S, Daniel Beauchamp R, Townsend CM Jr, Pour PM, Ishizuka J, Thompsen JC. Lovastatin inhibits pancreatic cancer growth regardless of Ras mutation. Pancreas 1994; 9: 657-61.
8. Soma RM, Donetti E, Parolini C, et al. HMG-CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993; 13: 571-78.
9. Maltess WA, Defendini R, Green RA, Sheridan KM, Doniey DK. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Clin Invest 1985; 76: 1748-54.
10. Kasiske BL, Lee HS, Kim Y, O'Donnell MP, Keane WF. Independent effects of cholesterol (CHOL) and HMG-CoA reductase inhibition on chronic vascular rejection in rats. J Am Soc Nephrol 1992; 3: 843.
11. Chojnacki T, Dallner G. The biological role of dolichol. Biochem J 1988; 251: 1-9.
12. Pérez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994; 199: 1209-15.
13. Elmberger PG, Kalén A, Lund E, et al. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991; 32: 935-40.
14. Pappu AS, Illingworth DR. Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia. J Lab Clin Med 1989; 114: 554-62.
15. Duggan DE, Chen TW, Bayne WF, et al. The physiological disposition of lovastatin. Drug Met Dispos 1989; 17: 166-73.
16. Pan HY, Devault AR, Wang-Iverson D, Ivoshkiv E, Swanson BN, Sugerman AA. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30: 1128-35.
17. Neuman A, Clutterbuck RD, DeLord C, Powles RL, Catovsky D, Moillar JL. The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation. J Investig Med 1995; 43: 269-74.
18. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after transplantation. N Engl J Med 1995; 333: 621-27.